We hereby submit the Outcome of Board Meeting held On May 28, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Speciality Medicines Ltd reported strong full-year FY2026 results with revenue from operations growing 29.2% to Rs 7,528.51 Lakhs from Rs 5,827.14 Lakhs in FY2025. Net profit surged 81.1% to Rs 1,303.29 Lakhs from Rs 719.63 Lakhs, while EPS improved to Rs 20.11 from Rs 11.79. The company completed its IPO in March 2026, raising Rs 2,914 Lakhs, and the auditors issued an unmodified opinion confirming clean financials. The company has startup recognition under Section 80-IAC providing tax benefits. Cash position strengthened significantly with closing cash at Rs 2,454.56 Lakhs vs Rs 84.58 Lakhs prior year.
Strong profitability growth with net profit up 81% and revenue up 29% reflects healthy business momentum post-IPO. Unmodified audit opinion signals no financial red flags for investors. The substantial cash raise from IPO provides runway for expansion activities.